Jeff Yass’s PharmaCyte Biotech PMCB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-2,100
Closed -$116K – 12890
2023
Q1
$116K Buy
2,100
+158
+8% +$8.82K ﹤0.01% 11164
2022
Q4
$108K Sell
1,942
-1,890
-49% -$103K ﹤0.01% 10899
2022
Q3
$175K Sell
3,832
-4,231
-52% -$203K ﹤0.01% 11030
2022
Q2
$346K Buy
+8,063
New +$335K ﹤0.01% 9188
2022
Q1
– Sell
-1,500
Closed -$71K – 13750
2021
Q4
$71K Buy
+1,500
New +$78.5K ﹤0.01% 12368

Other funds holding PMCB

Jeff Yass's PMCB Position: Q3 2026 in Review

Jeff Yass reduced its PharmaCyte Biotech (PMCB) stake by 33% in Q3 2026, selling an estimated $8.14K and leaving 1,582 shares worth $12.3K. The position accounts for ﹤0.01% of the portfolio, ranked #13205.

Jeff Yass first reported a position in PMCB in Q1 2022 and has held it in 13 quarters since. The position peaked at $311K in Q1 2023. 20 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

  • Jeff Yass held 1,582 shares of PharmaCyte Biotech worth $12.3K as of Q3 2026.
  • Jeff Yass sold 779 PharmaCyte Biotech shares in Q3 2026, an estimated $8.14K.
  • PharmaCyte Biotech made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #13205 holding.
  • Jeff Yass first reported a position in PharmaCyte Biotech in Q1 2022 and has held it in 13 quarters since.
  • Jeff Yass's PharmaCyte Biotech position peaked at $311K in Q1 2023.
  • 20 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.